Skip to main content
Premium Trial:

Request an Annual Quote

Rules-Based Medicine Acquires Satoris Biomarker IP

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rules-Based Medicine today said that it has acquired intellectual property assets covering biomarker technology from Satoris.

The deal includes biomarkers and biomarker panels for clinical research use for Alzheimer's disease, frontal temporal dementia, Parkinson's disease, and other central nervous system conditions.

Two years ago, Redwood City, Calif.-based Satoris had signed an agreement to distribute RBM's DiscoveryMAP panel for neurology research. It also sells its own Dementia Discrimination panel, which it said is used to differentiate Alzheimer's patients from patients with other forms of dementia.

"These assets from Satoris will be an important contributor as we continue to develop research and diagnostic offerings for neurodegenerative illnesses which affect millions of individuals and families," Craig Benson, president and CEO of Rules-Based Medicine, said in a statement.

Financial terms of the agreement were not disclosed.

Austin, Texas-based RBM agreed last month to be acquired by Myriad Genetics for $80 million.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.